The Signal
$IOVA posted Q3 earnings (11/5) that flip the narrative from risk to execution: $122M revenue, 60% gross margin, $382M cash runway into 2029, and EPS improvement from -$0.25 (Q3 2025) to -$0.05 (Q3 2026). sBLA filing for biomarker-stratified NSCLC (KRAS WT cohort, 85.7% ORR + pembro frontline) locks a second regulatory pathway with higher efficacy density than broad-label attempt. Simultaneously, $AQST Q3 earnings (11/3 AH, 11/4 call) confirm Anaphylm NDA resubmission momentum—PharmFilm solves 30-year portability gap vs. EpiPen incumbency. Neither play requires AI hype. Both require manufacturing scale and payer adoption. Street has priced execution risk, not optionality into profitability.
What's Moving
- $IOVA (NSCLC biomarker stratification + profitability glide) — Q3 beat ($122M rev, -$0.05 EPS, $382M cash) validates precision TIL manufacturing moat (150+ ATCs operationalized). sBLA filing for KRAS WT cohort + new LUN-202 cohort removes clinical binary; 85.7% ORR frontline durability justifies secondary registration. $20–25M floor into 2H27 sBLA; 7x melanoma TAM expansion unlocks higher ceiling. (via @biotechscanner)
- $AQST (Anaphylm pre-PDUFA + $2B epinephrine TAM) — Q3 earnings confirm NDA resubmission integrated with FDA feedback (HF trial + PK trial results "better than expected"). PharmFilm delivery solves portability; launch hiring (Medical Liaisons, Regional Directors) operationalizing. Allergy KOL enthusiasm locked post-CRL. $473M cap vs. $1.8B post-approval floor = 3.8x upside into 1H27. (via @biotechscanner)
- Manufacturing footprint as biotech-AI moat — $AQST's 50M+/year manufacturing business + $IOVA's 150+ ATC cell therapy capability demonstrate that biomarker-stratified oncology + precision delivery are capital-intensive, not AI-proof plays. Reduces commodity biotech risk; locks TAM defensibility.
Crosscurrents
- $MDGL safety allegation noise vs. earnings reality — Whistleblower complaint (Charlton v. Madrigal, filed Oct 2026) alleges retaliation under Sarbanes-Oxley; company denies. Q3 revenue $431M (beat). @adamfeuerstein flagged; @biotech2k1 dismisses as "fearmongering" (55k+ patients on drug, 100% YoY growth). Safety risk is real if substantiated; margin risk if not. Stock reaction: modest. Execution > noise. (via @adamfeuerstein, @biotech2k1)
- $RVMD Rasonque launch velocity vs. expectations cliff — $198M Q3 sales + 5k+ patients in first 5 weeks. @adamfeuerstein reports buyside now models $80–100M Q3 (if partial quarter paid), $400–500M Q4. Consensus was $26M. Stratospheric expectations embedded; payer adoption clarity critical into Q4. Risk reimbursement tightening post-launch euphoria.
Tradecraft
Desk Notes
- @biotechscanner — All-in on precision TIL + Anaphylm thesis; largest $IOVA holding, added significantly to $AQST; expects profitability Q1 2027 for Iovance.
- @biotech2k1 — Fading biotech rally into year-end; selling into FOMO; rotating cash to tech parts suppliers (low debt, high margin). Sees data center capex headwind from blue-wave regulation, not biotech upside.
- @adamfeuerstein — Tracking $RVMD launch traction + $MDGL safety allegations in real time; bullish on $RVMD commercial runway; skeptical of safety noise unless substantiated.